BTIG raised the firm’s price target on Insulet (PODD) to $380 from $370 and keeps a Buy rating on the shares after the company’s Investor Day presentation. Insulet aims to be “omnipresent” in type-1 and type-2 diabetes as it targets a “sustained multi-year growth”, the analyst tells investors in a research note. BTIG adds it sees Insulet’s long-range targets as achievable, and the firm is pleased to hear that the company is undertaking various initiatives to drive growth in both the near and long term.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet’s Promising Growth Potential: A Buy Rating Despite Market Skepticism
- Insulet’s Ambitious Growth Targets and Strategic Initiatives Reinforce Buy Rating with Revised Price Target of $380
- Insulet’s Strategic Growth and Innovation Drive ‘Buy’ Rating with $360 Price Target
- Insulet’s Promising Growth: Buy Rating Backed by Strong Sales Projections and Innovation Investment
- Insulet’s Strong Market Position and Growth Prospects Justify Buy Rating